Skip to main content

Gene Editing in the Liver

Improving Gene Editing in the Liver


Technique shows promise for treating genetic diseases that require correction or replacement of defective genes in the liver.

Advances in genome editing have raised hopes for curing a wide range of disorders caused by single genetic mutations. Hundreds of such conditions could potentially be treated by correcting disease-causing genes in the liver alone.

Cells in the liver can be easily reached by gene editing tools. Early studies that used gene editing to shut down the activity of genes in the liver have shown promise. But many more disorders are caused by defective genes that need to be repaired to restore normal function. A gene editing approach called homology-directed repair can potentially replace parts or all of a defective gene. But this technique requires actively dividing cells to work.

A research team led by Drs. William Lagor from Baylor College of Medicine and Gang Bao from Rice University have been developing a homology-directed repair system called Repair Drive to give genetically edited cells a jumpstart using the liver’s natural growth processes. The system uses small interfering RNA (siRNA) to temporarily shut down an essential gene called Fah in liver cells. This knock-down process can be tailored to last for specific periods of time.

To deliver a healthy version of the gene that needs repair or replacement, the team attaches it to a version of Fah that is resistant to the siRNA inhibition. This repair package is then delivered to liver cells using a modified version of a virus. In theory, this combination would let populations of gene-edited cells grow while removing unedited cells.

In a set of new studies, funded in part by NIH, the researchers tested Repair Drive in several mouse models. Their results were published on February 12, 2025, in Science Translational Medicine.

The researchers observed rapid growth of cells edited with Repair Drive after siRNA administration. The mice showed signs of mild liver damage, as expected. But this damage resolved by 12 weeks after treatment.

To look at long-term safety, the team used Repair Drive to deliver a gene called FIX to adult mice. Defects in FIX cause a type of hemophilia, a bleeding disorder, in people. The team used siRNA to suppress normal Fah for 3 months, then examined the mouse livers after a year.

They found that Repair Drive mice secreted about five times more FIX after a year than they did before gene repair. The amount of FIX produced by the repaired liver cells would be enough to prevent dangerous bleeding events in people with FIX defects. By a year after treatment, the mice had normal-appearing livers and normal Fah activity, or expression.

Notably, Repair Drive did not raise liver cancer rates in the mice. Two mice in each group had small areas of abnormal growth in their livers, which are common for mice of this age, but these did not show cancerous changes.

“Think of a yard full of weeds—that is like a diseased liver. The weeds are cells that don’t express the gene that they should be expressing,” Lagor explains. “Using Repair Drive, we come in and kill off the weeds, or the unhealthy cells. In doing so, we basically create space for fresh new grass plugs (i.e. corrected cells) to grow and make a new lawn. We also spent a lot of effort making sure that the weed killing only happens for a brief period of time, and that the lawn is healthy in the long run.”

More work is needed to test the Repair Drive system in models that have other common liver diseases, such as viral infections or fatty liver disease. The technique also needs to be tested for safety in larger animal models.

Liver disease, hepatology, cirrhosis, fibrosis, liver function, fatty liver, hepatitis, liver detox, bile production, liver enzymes, hepatocytes, liver cancer, transplantation, oxidative stress, cholestasis, NAFLD, ALD, viral hepatitis, hepatic metabolism, liver regeneration,

#LiverHealth, #Hepatology, #Cirrhosis, #FattyLiver, #Hepatitis, #LiverFunction, #LiverDetox, #LiverCare, #LiverSupport, #LiverEnzymes, #LiverDisease, #LiverCancer, #LiverTransplant, #NAFLD, #ALD, #LiverHealing, #LiverRegeneration, #LiverWellness, #BileProduction, #OxidativeStress

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more